The clinical application of preimplantation genetic diagnosis for the patient affected by congenital contractural arachnodactyly and spinal and bulbar muscular atrophy

Abstract

<div class="section"> <a class="named-anchor" id="d1940440e181"> <!-- named anchor --> </a> <h5 class="section-title" id="d1940440e182">Purpose</h5> <p id="d1940440e184">To investigate the usefulness of preimplantation genetic diagnosis (PGD) for the patient affected by congenital contractural arachnodactyly (CCA) and spinal and bulbar muscular atrophy (SBMA). </p> </div><div class="section"> <a class="named-anchor" id="d1940440e186"> <!-- named anchor --> </a> <h5 class="section-title" id="d1940440e187">Methods</h5> <p id="d1940440e189">Multiple displacement amplification (MDA) was performed for whole genome amplification (WGA) of biopsied trophectoderm (TE) cells. Direct mutation detection by sequencing and next-generation sequencing (NGS)-based single nucleotide polymorphism (SNP) haplotyping were used for CCA diagnosis. Direct sequencing of the PCR products and sex determination by amplification of sex-determining region Y (SRY) gene were used for SBMA diagnosis. After PGD, the unaffected blastocyst (B4) was transferred in the following frozen embryo transfer (FET). </p> </div><div class="section"> <a class="named-anchor" id="d1940440e191"> <!-- named anchor --> </a> <h5 class="section-title" id="d1940440e192">Results</h5> <p id="d1940440e194">In this PGD cycle, sixteen MII oocytes were inseminated by ICSI with testicular spermatozoa. Four blastocysts (B4, B5, B10, B13) were utilized for TE cell biopsy on day 5 after ICSI. After PGD, B4 was unaffected by CCA and SBMA. B5 was affected by CCA and carried SBMA. B10 was unaffected by CCA and carried SBMA. B13 was affected by CCA and unaffected by SBMA. B4 was the only unaffected blastocyst and transferred into the uterus for the subsequent FET cycle. The accuracy of PGD was confirmed by amniocentesis at 21 weeks of gestation. A healthy boy weighing 2850 g was born by cesarean section at the 38th week of gestation. </p> </div><div class="section"> <a class="named-anchor" id="d1940440e196"> <!-- named anchor --> </a> <h5 class="section-title" id="d1940440e197">Conclusions</h5> <p id="d1940440e199">PGD is a valid screening tool for patienst affected of CCA and SBMA to prevent transmission of these genetic diseases from parents to children. </p> </div>